Rubius_Logo.jpg
Rubius Therapeutics to Announce Second Quarter 2018 Financial Results
August 21, 2018 16:05 ET | Rubius Therapeutics
CAMBRIDGE, Mass., Aug. 21, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies,...
Rubius_Logo.jpg
Rubius Therapeutics to Acquire Manufacturing Facility in Smithfield, Rhode Island to Produce Red Cell Therapeutics
July 25, 2018 08:30 ET | Rubius Therapeutics
CAMBRIDGE, Mass., July 25, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies,...
Rubius_Logo.jpg
Rubius Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
July 23, 2018 08:30 ET | Rubius Therapeutics
CAMBRIDGE, Mass., July 23, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biotechnology company pioneering the development of a new class of ready-to-use cellular...
Rubius Therapeutics Announces Pricing of Initial Public Offering
July 17, 2018 22:44 ET | Rubius Therapeutics
CAMBRIDGE, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies,...